PMID- 38164192
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240103
IS  - 1662-5161 (Print)
IS  - 1662-5161 (Electronic)
IS  - 1662-5161 (Linking)
VI  - 17
DP  - 2023
TI  - Serum neurofilament light chain levels in patients with cognitive deficits and 
      movement disorders: comparison of cerebrospinal and serum neurofilament light 
      chain levels with other biomarkers.
PG  - 1284416
LID - 10.3389/fnhum.2023.1284416 [doi]
LID - 1284416
AB  - BACKGROUND: Serum neurofilament light chain (S NfL) is a non-specific marker of 
      neuronal damage, including Alzheimer's disease (AD). We aimed to verify the 
      reference interval (RI) of serum NfL using a highly sensitive ELISA, and to 
      estimate the optimal cut-off value for neuronal damage. Our second objective was 
      to compare NfL in cerebrospinal fluid (CSF) and serum (S) with the routine 
      neurodegeneration biomarkers used in AD, and to assess their concentrations 
      relative to the degree of cognitive deficit. METHODS: Samples from 124 healthy 
      volunteers were used to estimate the S NfL RI. For the comparison study, we used 
      CSF and S samples from 112 patients with cognitive disorders. Cognitive functions 
      were assessed using the mini-mental state examination. ELISA assays were used to 
      determine the CSF and S NfL levels, CSF beta-amyloid peptide(42) (Abeta(42)), CSF 
      beta-amyloid peptide(40) (Abeta(40)), CSF total tau protein (tTau), CSF phosphorylated 
      tau protein (pTau), and CSF alpha-synuclein (alphaS). RESULTS: The estimated RI of S 
      NfL were 2.25-9.19 ng.L(-1). The cut-off value of S NfL for assessing the degree 
      of neuronal impairment was 10.5 ng.L(-1). We found a moderate statistically 
      significant correlation between S NfL and CSF Abeta(42) in the group with movement 
      disorders, without dementia (r(s) = 0.631; p = 0.016); between S NfL and CSF 
      Abeta(40) in the group with movement disorder plus dementia (r(s) = -0.750; p = 
      0.052); between S NfL and CSF tTau in the control group (r(s) = 0.689; p = 
      0.009); and between S NfL and CSF pTau in the control group (r(s) = 0.749; p = 
      0.003). The non-parametric Kruskal-Wallis test revealed statistically significant 
      differences between S NfL, CSF NfL, CSF Abeta(42), CSF tTau, and CSF pTau and 
      diagnosis within groups. The highest kappa coefficients were found between the 
      concentrations of S NfL and CSF NfL (kappa = 0.480) and between CSF NfL and CSF tTau 
      (kappa = 0.351). CONCLUSION: Our results suggested that NfL and tTau in CSF of 
      patients with cognitive decline could be replaced by the less-invasive 
      determination of S NfL using a highly sensitive ELISA method. S NfL reflected the 
      severity of cognitive deficits assessed by mini-mental state examination (MMSE). 
      However, S NfL is not specific to AD and does not appear to be a suitable 
      biomarker for early diagnosis of AD.
CI  - Copyright (c) 2023 Novobilsky, Bartova, Licha, Bar, Stejskal and Kusnierova.
FAU - Novobilsky, Richard
AU  - Novobilsky R
AD  - Department of Neurology, University Hospital Ostrava, Ostrava, Czechia.
AD  - Department of Clinical Neurosciences, University of Ostrava, Ostrava, Czechia.
FAU - Bartova, Petra
AU  - Bartova P
AD  - Department of Neurology, University Hospital Ostrava, Ostrava, Czechia.
AD  - Department of Clinical Neurosciences, University of Ostrava, Ostrava, Czechia.
FAU - Licha, Karin
AU  - Licha K
AD  - Department of Clinical Biochemistry, Institute of Laboratory Medicine, University 
      Hospital Ostrava, Ostrava, Czechia.
FAU - Bar, Michal
AU  - Bar M
AD  - Department of Neurology, University Hospital Ostrava, Ostrava, Czechia.
AD  - Department of Clinical Neurosciences, University of Ostrava, Ostrava, Czechia.
FAU - Stejskal, David
AU  - Stejskal D
AD  - Department of Clinical Biochemistry, Institute of Laboratory Medicine, University 
      Hospital Ostrava, Ostrava, Czechia.
AD  - Institute of Laboratory Medicine, University of Ostrava, Ostrava, Czechia.
FAU - Kusnierova, Pavlina
AU  - Kusnierova P
AD  - Department of Clinical Biochemistry, Institute of Laboratory Medicine, University 
      Hospital Ostrava, Ostrava, Czechia.
AD  - Institute of Laboratory Medicine, University of Ostrava, Ostrava, Czechia.
LA  - eng
PT  - Journal Article
DEP - 20231214
PL  - Switzerland
TA  - Front Hum Neurosci
JT  - Frontiers in human neuroscience
JID - 101477954
PMC - PMC10757912
OTO - NOTNLM
OT  - cognitive deficit
OT  - high-sensitivity ELISA
OT  - mini-mental state examination
OT  - neurofilament light chain
OT  - serum
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/01/02 11:45
MHDA- 2024/01/02 11:46
PMCR- 2023/01/01
CRDT- 2024/01/02 03:37
PHST- 2023/08/28 00:00 [received]
PHST- 2023/11/13 00:00 [accepted]
PHST- 2024/01/02 11:46 [medline]
PHST- 2024/01/02 11:45 [pubmed]
PHST- 2024/01/02 03:37 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fnhum.2023.1284416 [doi]
PST - epublish
SO  - Front Hum Neurosci. 2023 Dec 14;17:1284416. doi: 10.3389/fnhum.2023.1284416. 
      eCollection 2023.